TWI925859B - 抗血小板藥物及其用途 - Google Patents

抗血小板藥物及其用途

Info

Publication number
TWI925859B
TWI925859B TW110127818A TW110127818A TWI925859B TW I925859 B TWI925859 B TW I925859B TW 110127818 A TW110127818 A TW 110127818A TW 110127818 A TW110127818 A TW 110127818A TW I925859 B TWI925859 B TW I925859B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
alkyl
group
compounds
Prior art date
Application number
TW110127818A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214609A (zh
Inventor
自強 顧
袁超 張
何公欣
侯凱
吳豪
Original Assignee
大陸商上海柯君醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海柯君醫藥科技有限公司 filed Critical 大陸商上海柯君醫藥科技有限公司
Publication of TW202214609A publication Critical patent/TW202214609A/zh
Application granted granted Critical
Publication of TWI925859B publication Critical patent/TWI925859B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
TW110127818A 2020-07-29 2021-07-29 抗血小板藥物及其用途 TWI925859B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2020/105513 2020-07-29
CN2020105513 2020-07-29

Publications (2)

Publication Number Publication Date
TW202214609A TW202214609A (zh) 2022-04-16
TWI925859B true TWI925859B (zh) 2026-05-21

Family

ID=80037185

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110127818A TWI925859B (zh) 2020-07-29 2021-07-29 抗血小板藥物及其用途

Country Status (14)

Country Link
US (2) US12410132B2 (cg-RX-API-DMAC7.html)
EP (2) EP4342532B1 (cg-RX-API-DMAC7.html)
JP (1) JP7899159B2 (cg-RX-API-DMAC7.html)
KR (2) KR102906376B1 (cg-RX-API-DMAC7.html)
CN (4) CN119552111B (cg-RX-API-DMAC7.html)
AR (1) AR123078A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021317436A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001595A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186645A1 (cg-RX-API-DMAC7.html)
ES (1) ES3046366T3 (cg-RX-API-DMAC7.html)
IL (1) IL299979A (cg-RX-API-DMAC7.html)
MX (1) MX2023001232A (cg-RX-API-DMAC7.html)
TW (1) TWI925859B (cg-RX-API-DMAC7.html)
WO (1) WO2022022559A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202339745A (zh) * 2022-01-28 2023-10-16 大陸商上海柯君醫藥科技有限公司 抗血小板藥物的藥物組合物及其用途
CN116813532B (zh) * 2023-06-29 2026-05-15 上海柯君医药科技有限公司 一种哌啶化合物的制备方法
WO2025108307A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐、其制备方法及应用
WO2025108300A1 (zh) 2023-11-24 2025-05-30 上海柯君医药科技有限公司 一种含哌啶环化合物的苯磺酸盐的晶型、其制备方法及应用
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119176829B (zh) * 2024-11-26 2025-04-15 上海柯君医药科技有限公司 一种哌啶环化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法
CN119371453A (zh) * 2024-12-30 2025-01-28 上海柯君医药科技有限公司 一种抗血小板药物中间体的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008811A1 (en) * 1996-08-28 1998-03-05 Sankyo Company, Limited Cyclic amine derivatives
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570048A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CN104379589A (zh) * 2012-05-07 2015-02-25 塞利克斯比奥私人有限公司 抗血小板药剂的前药
CA2880898A1 (en) * 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
CN103626694A (zh) * 2012-08-29 2014-03-12 中国药科大学 不饱和环胺衍生物、其制备方法及其医药用途
NO2721243T3 (cg-RX-API-DMAC7.html) * 2014-10-01 2018-10-20
CN119019320B (zh) * 2024-10-29 2025-03-11 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法
CN119192061B (zh) * 2024-11-28 2025-05-13 上海柯君医药科技有限公司 一种含哌啶环的化合物的纯化方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008811A1 (en) * 1996-08-28 1998-03-05 Sankyo Company, Limited Cyclic amine derivatives
CN106554368A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途
CN106554303A (zh) * 2015-09-25 2017-04-05 陕西合成药业股份有限公司 噻吩并吡啶类衍生物及其制备方法和用途

Also Published As

Publication number Publication date
CN116194459A (zh) 2023-05-30
KR20230047425A (ko) 2023-04-07
IL299979A (en) 2023-03-01
TW202214609A (zh) 2022-04-16
JP7899159B2 (ja) 2026-08-03
CN119033782A (zh) 2024-11-29
KR20250073569A (ko) 2025-05-27
MX2023001232A (es) 2023-05-15
US20250333382A1 (en) 2025-10-30
EP4342532C0 (en) 2025-09-03
US20240279178A1 (en) 2024-08-22
AU2021317436A1 (en) 2023-02-23
ES3046366T3 (en) 2025-12-01
CN119552111A (zh) 2025-03-04
CA3186645A1 (en) 2022-02-03
EP4342532B1 (en) 2025-09-03
CN119552111B (zh) 2026-01-02
EP4188935A1 (en) 2023-06-07
KR102906376B1 (ko) 2025-12-30
AR123078A1 (es) 2022-10-26
WO2022022559A1 (en) 2022-02-03
CN119033782B (zh) 2025-04-25
US12410132B2 (en) 2025-09-09
EP4342532A3 (en) 2024-07-17
EP4188935A4 (en) 2024-07-17
EP4342532A2 (en) 2024-03-27
BR112023001595A2 (pt) 2023-04-04
CN117343000A (zh) 2024-01-05
JP2023535815A (ja) 2023-08-21

Similar Documents

Publication Publication Date Title
EP4172216A4 (en) BIFUNCTIONAL SUPERKINE AND USES THEREOF
IL299979A (en) Antiplatelet drugs and their uses
EP4305030A4 (en) HETEROCYCLES AND THEIR USES
EP4096651A4 (en) COMPOUNDS AND THEIR USES
EP4096668A4 (en) COMPOUNDS AND USES THEREOF
EP4096664A4 (en) COMPOUNDS AND USES THEREOF
EP4215208A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
EP4165049A4 (en) ISOTRYPTAMIN PSYCOPLASTIOGENS AND USES THEREOF
EP4247815A4 (en) COMPOUNDS AND USES THEREOF
EP4037670A4 (en) 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF
EP4233882A4 (en) Mitochondria comprising anticancer drug and use thereof
EP4326340A4 (en) MODIFIED POLYPEPTIDES AND THEIR USES
EP4337211A4 (en) COMPOUNDS AND THEIR USES
EP4140480A4 (en) DRUG COMBINATION AND USE
EP4342492A4 (en) PHARMACEUTICAL COMBINATION AND ITS USE
EP4129282A4 (en) PHARMACEUTICAL ASSOCIATION AND ITS USE
HK40081165A (en) Pharmaceutical combination comprising tno155 and nazartinib
HK40108849A (en) Nitrophenyl-acrylamides and uses thereof
HK40103610A (en) Pharmaceutical combination and use thereof
HK40102892A (en) Heterocycles and uses thereof
AU2020900439A0 (en) Tpv-2l variants and uses thereof
HK40084386A (en) Substituted pyrazolo-pyrimidines and uses thereof
HK40115119A (en) Lilrb polypeptides and uses thereof
HK40107538A (en) Staple-containing polypeptides and application thereof
HK40109989A (en) Nkp46-binding polypeptides and uses thereof